Ribosomal protein L23a pseudogene 66 (RPL23AP66)

Ribosomal protein L23a pseudogene 66 (RPL23AP66) is a human processed pseudogene related to the ribosomal protein L23a gene. Unlike the functional RPL23A gene, which encodes a component of the 60S ribosomal subunit necessary for protein synthesis, RPL23AP66 does not produce a functional protein product and has no established biological function, disease relevance, or therapeutic applications[4][6]. Pseudogenes like RPL23AP66 are common, arising from gene duplication or retrotransposition events. They may be transcribed, but currently there is no evidence for their involvement in pathogenic processes or as drug targets, nor is RPL23AP66 considered a clinically relevant biomarker[4][6]. There is no evidence to suggest that RPL23AP66 participates in cellular pathways, interacts with drugs, or presents notable safety concerns as a therapeutic target. RPL23AP66 is a pseudogene, not a functional gene or protein target[4][6]. It is not considered a receptor, enzyme, transporter, or any established druggable target. If the intended target is the functional ribosomal protein L23a (encoded by RPL23A, not RPL23AP66), that is a distinct entity with different biological significance[3][10]. No disease associations, mechanistic roles, or approved/experimental drugs are documented for RPL23AP66. The entry is not a valid therapeutic target according to current classification systems.

Other names

RPL23A_30_1207RPL23AP66